Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp. (EXAS)
NASDAQ:EXAS
EXAS Stock Chart & Stats
$103.35
-$1.49(-2.61%)
At close: 4:00 PM EST
$103.35
-$1.49(-2.61%)
Day’s Range― - ―
52-Week Range$38.81 - $103.67
Previous CloseN/A
Volume846.89K
Average Volume (3M)2.19M
Market Cap
$19.73B
Enterprise Value$21.29B
Total Cash (Recent Filing)$964.71M
Total Debt (Recent Filing)$2.52B
Price to Earnings (P/E)―
Beta0.12
Next Earnings
May 13, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding190,888,210
10 Day Avg. Volume1,944,615
30 Day Avg. Volume2,190,485
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)7.98
Price to Sales (P/S)5.90
P/FCF Ratio53.71
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue6.56
Enterprise Value/Gross Profit9.41
Enterprise Value/Ebitda499.63
Forecast
1Y Price Target
$105.00Price Target Upside1.60% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)0.22
Revenue Forecast (FY)$3.68B
Bulls Say, Bears Say
Bulls Say
Commercial PerformanceStrong screening revenue growth accelerated from 14% to 22% driven by expanded hiring and improved sales force productivity, supporting a rebound in Cologuard volumes.
Product Pipeline & Market PositionDevelopment of liquid biopsy assays, and CMS coverage for Oncodetect, positions the company to capture meaningful share of the $20 billion-plus minimal residual disease market.
Sales Force Leverage And New Test LaunchesRecent launches of new stool and blood screening tests combined with a large commercial sales force are likely to increase testing adoption and sustain long-term revenue growth.
Bears Say
Acquisition Competition RiskThe roughly $23 billion enterprise value is large relative to most potential acquirers' capacity, making a higher competing bid unlikely and constraining deal-driven upside.
Profitability PressureA large research and development charge tied to a collaboration reduced profitability, and the company is expected to be dilutive in 2026 and 2027, pressuring near-term earnings per share.
Valuation Cap / Limited UpsideAnalyst downgrades to Hold or Neutral reflect shares trading near the $105 takeout price, leaving limited upside for investors.
Exact Sciences News
EXAS FAQ
What was Exact Sciences Corp.’s price range in the past 12 months?
Exact Sciences Corp. lowest stock price was $38.81 and its highest was $103.67 in the past 12 months.
What is Exact Sciences Corp.’s market cap?
Exact Sciences Corp.’s market cap is $19.73B.
When is Exact Sciences Corp.’s upcoming earnings report date?
Exact Sciences Corp.’s upcoming earnings report date is May 13, 2026 which is in 70 days.
How were Exact Sciences Corp.’s earnings last quarter?
Exact Sciences Corp. released its earnings results on Feb 13, 2026. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.108 by -$0.342.
Is Exact Sciences Corp. overvalued?
According to Wall Street analysts Exact Sciences Corp.’s price is currently Undervalued.
Does Exact Sciences Corp. pay dividends?
Exact Sciences Corp. does not currently pay dividends.
What is Exact Sciences Corp.’s EPS estimate?
Exact Sciences Corp.’s EPS estimate is -0.17.
How many shares outstanding does Exact Sciences Corp. have?
Exact Sciences Corp. has 190,888,210 shares outstanding.
What happened to Exact Sciences Corp.’s price movement after its last earnings report?
Exact Sciences Corp. reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.108. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Exact Sciences Corp.?
Currently, no hedge funds are holding shares in EXAS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exact Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$105.00 (1.60% Upside)
$105.00 (1.60% Upside)
Blogger Sentiment
Bullish
EXAS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 6.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.18%
12-Months-Change
Fundamentals
Return on Equity
-8.66%
Trailing 12-Months
Asset Growth
-1.42%
Trailing 12-Months
Company Description
Exact Sciences Corp.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
EXAS Company Deck
EXAS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Exact Sciences reported strong financial and operational performance with significant revenue growth driven by Cologuard and new product launches. However, there were challenges in maintaining gross margins and completing payer contracts for Cologuard Plus.View all EXAS earnings summariesEXAS Revenue Breakdown
74.59% Screening
25.17% Precision Oncology
0.24% COVID-19 Testing
EXAS Stock 12 Month Forecast
Average Price Target
$105.00
▲(1.60% Upside)
Technical Analysis
Ownership Overview
1.20% Insiders
31.73% Mutual Funds
11.13% Other Institutional Investors
42.79% Public Companies and
Individual Investors